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Abstract
Background
Subclinical hypothyroidism is associated with a number of cardiovascular risk factors, yet
only limited data exist on long-term outcome of levothyroxine treatment of this condition with
respect to hard end-points. The aim of this retrospective cohort study was to determine ef-
fects of levothyroxine treatment on myocardial infarction (MI), cardiovascular death and all-
cause mortality, in patients with subclinical hypothyroidism.
Methods and Results
Primary care patients aged 18 years and older that underwent thyroid function tests be-
tween 2000 and 2009 were enrolled. Participants were identified by individual-level linkage
of nationwide registers. Patients with subclinical hypothyroidism at baseline were included
in the study. Exclusion criteria included a history of thyroid disease, related medication or
medication affecting thyroid function. The total cohort comprised 628,953 patients of which
12,212 (1.9%) had subclinical hypothyroidism (mean age 55.2 [SD ± 18.8] years; 79.8% fe-
male). Within the first six months 2,483 (20.3%) patients claimed a prescription for levothyr-
oxine. During a median follow-up of 5.0 (IQR: 5.2) years, 358 MI’s and 1,566 (12.8%)
deaths were observed. Out of these, 766 of the deaths were cardiovascular related. No ben-
eficial effects were found in levothyroxine treated patients on MI (IRR 1.08 [95% CI: 0.81 to
1.44]), cardiovascular death (IRR 1.02 [95% CI: 0.83 to 1.25]) or all-cause mortality (IRR
1.03 [95% CI: 0.90 to 1.19]), except in patients under the age of 65 years (IRR 0.63 [95% CI:
0.40 to 0.99]).
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Conclusion
Levothyroxine substitution in subclinical hypothyroid patients does not indicate an associa-
tion with lower mortality or decreased risk of MI.
Introduction
Subclinical hypothyroidism is biochemically defined as raised serum thyroid-stimulating hor-
mone (TSH) concentrations with simultaneously occurring normal circulating thyroxine
(FT4).[1] The condition is associated with a number of cardiovascular risk factors such as dia-
stolic hypertension,[2, 3] weight gain,[4–6] insulin resistance,[7] hypercholesterolemia,[8] dys-
lipidaemia,[9] coronary heart disease[10, 11] and ischemic heart disease.[12–16] However, a
number of questions still remain concerning the treatment of subclinical hypothyroidism with
levothyroxine, and controversy exists regarding the management of the condition.[17–19] Cur-
rent guidelines recommend that individuals under the age of 65 years with a serum TSH value
above 10 mIU/L and symptoms of hypothyroidism should be treated with levothyroxine, but
opinions regarding mild subclinical hypothyroidism (TSH 10 mIU/L) and patients over the
age of 65 years vary.[20, 21] Some endocrinologists recommend that most patients with sub-
clinical hypothyroidism, including those with a serum TSH value below 10 mIU/L, should be
treated.[22]
The prevalence of subclinical hypothyroidism is approximately 4% in the general popula-
tion, it is more common in females, and increases with age.[23] Roughly 3–5% of patients with
subclinical hypothyroidism progress to overt hypothyroidism annually, with higher frequen-
cies in persons with elevated thyroxine peroxidase autoantibody levels.[24] A clinical random-
ized trial is currently in the process of recruiting patients over the age of 65 years with
subclinical hypothyroidism with the aim to investigate the effects of levothyroxine.[25]
Treatment of the condition remains controversial because it is still unknown whether inter-
vention with substitution therapy is beneficial on hard endpoints such as cardiovascular disease
and mortality.[26] This large register-based study was conducted to examine the hypothesis,
that substitution treatment with levothyroxine in patients with subclinical hypothyroidism re-
duces the risk of myocardial infarction (MI), cardiovascular death and all-cause mortality.
Methods
Data sources
Each resident in Denmark is provided with a permanent and unique identification number
which enables individual-level linkage between national administrative registers holding infor-
mation on healthcare usage.[27] Five registers were used in this study: 1) The Danish National
Patient Register, which has kept records of all hospital admissions since 1977. All admissions
have been registered with one main discharge diagnosis, and, if applicable, one or more supple-
mentary discharge diagnoses coded according to the International Classification of Diseases
(ICD-8 until 1994 and from 1994 ICD-10).[28] Vital status was obtained from 2) The Civil
Registration system, which records deaths for all Danish citizens.[27] Specific causes of death
were obtained from 3) The Danish Register of Causes of Death.[29] Information on medication
was obtained from 4) The Danish Register of Medicinal Product Statistics, which keeps records
on all claimed prescriptions (coded according to the international Anatomical Therapeutic
Chemical (ATC) Classification) from pharmacies in Denmark since 1994.[30] The register also
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holds information regarding quantity, strength, and date of dispensation as well as formulation
and the affiliation of the physician issuing the prescription. Annual incomes were retrieved
from 5) The Danish registers on personal income and transfer payments–The Danish Labour
Market.[31] Socioeconomic status was defined by the average yearly gross household income
in a 5-year period prior to inclusion in the study.
The study population
The study cohort comprised citizens of Copenhagen over the age of 18, who at referral of their
general practitioner underwent a thyroid function test at the Elective Laboratory of the Capital
Region, Copenhagen, in the period between 1 January 2000 and 31 December 2009. TSH and
FT4 were determined in serum by the commercially available ADVIA Centaur System (Bayer/
Siemens, Tarrytown, NY). Patients with previous thyroid dysfunction i.e. previous prescrip-
tions of thyroid hormones, anti-thyroid drugs or any thyroid-related hospital diagnoses were
excluded from the study. Patients were categorized according to their thyroid status at the time
of their first thyroid function test by traditional definitions of thyroid dysfunction (Table 1).
Subclinical hypothyroidism was categorized in two subdivisions: Grade I with mildly in-
creased TSH levels (5.0–10.0 mlU/l) and Grade II with severely increased TSH levels (> 10.0
mIU/l).[32, 33] Furthermore, patients were divided into above and below the age of 65 years.
Study design
The study was a register-based retrospective cohort study of patients with subclinical hypothy-
roidism in the period 2000–2009. Patients were divided into groups of untreated and treated
defined as those who initiated levothyroxine treatment within six months from the date of
their first thyroid function test. This definition was chosen to ensure that the thyroid function
test and subsequent prescription of levothyroxine had a causal relationship. Patients entered
the study at the time of their thyroid function test. The treated patients contributed with risk
time in the untreated group until they initiated levothyroxine treatment, at which they were
moved from the untreated group to the treated group. Patients left the study at death, emigra-
tion, or end-of-study.
Comorbidity and concomitant medical therapy
Comorbidities such as ischemic heart disease, heart failure, MI and stroke were identified from
The Danish National Patient Register (Table 2).
Charlson Comorbidity Index was calculated on basis of pre-specified diagnoses up to five
years prior to cohort entry.[34, 35] Medication known to affect thyroid function, such as thy-
roid hormones, anti-thyroid medications, lithium, amiodarone, and glucocorticoids,[36, 37]
were identified from The Danish Register of Medicinal Product Statistics.
Table 1. Definitions of thyroid disease and thyroid dysfunction levels.
Thyroid dysfunction deﬁnitions TSH FT4
Euthyroidism 0.2–5.0 mlU/L 9–22 pmol/L
Subclinical Hypothyroidism > 5.0 mlU/L 9–22 pmol/L
Grade I 5.0–10 mIU/L 9–22 pmol/L
Grade II > 10 mIU/L 9–22 pmol/L
doi:10.1371/journal.pone.0129793.t001
Levothyroxine Substitution in Patients with Subclinical Hypothyroidism
PLOSONE | DOI:10.1371/journal.pone.0129793 June 12, 2015 3 / 17
Dose and duration of treatment
The Danish Register of Medical Product Statistics does not hold information regarding pre-
scribed daily dosage of the medication. Therefore, we estimated the daily dosage when each
new prescription was dispensed, by calculating the average dosages from up to seven consecu-
tive prescriptions. This algorithm allowed the dosage to change when a new prescription was
dispensed. This method, used to determine the average treatment time and dose has previously
been described.[38, 39]
Outcomes
The primary outcome of interest was all-cause mortality, with the secondary outcomes being
MI, including fatal and non-fatal MI, and cardiovascular death, determined as death caused by
any diseases or conditions related to the cardiovascular system (Table 2). The MI diagnoses re-
ported to the registers have been validated and found reliable with a sensitivity of 91% and a
positive predictive value of 93%.[40]
Statistical analysis
Baseline characteristics are presented as numbers with percentages for categorical variables
and as means ± standard deviations (SD) for continuous variables. Median follow-up time and
average treatment time is reported with interquartile range (IQR). The incidence rates (IRs)
were calculated as number of events per 1000 person-years (py) stratified by levothyroxine sub-
stitution, age as a continuous variable and two grades of subclinical hypothyroidism. Poisson
regression models were constructed to estimate incidence rate ratios (IRRs, with 95% confi-
dence intervals [CIs]) for the outcomes. Poisson regression models were adjusted for age, gen-
der and Charlson Comorbidity Index and therefore included two time scales: calendar time
with bands split in 1-year periods after 1 January 2000 and duration since the first thyroid
function testing. Age was calculated at the beginning of each interval. Individuals were cen-
sored at the time of fatal or non-fatal event, at emigration or end of study (31 December 2009).
A 95% significance level was used in all analyses including the interactions testing.
Table 2. Diagnoses (ICD-8 and ICD-10) andmedication (ATC) codes used in the study.
Diseases & medication ICD & ATC codes
Thyroid diseases and medication
Hypothyroidism ICD-10: E02-03, E063
Hyperthyroidism ICD-10: E05, E062
Any thyroid related disease ICD-8: 240–246, ICD-10: E00-E06, O905
Levothyroxine ATC: H03AA01
Methimazole ATC: H03BB01, H03BB02
Propylthiouracil (PTU) ATC: H03BA02
Cardiovascular disease and medication
Ischemic heart disease ICD-8: 411–414, ICD-10: I20, I23-I2
Myocardial Infarction (MI) ICD-8: 410, ICD-10: I21, I22
Any cardiovascular related diagnoses ICD-10: I00-I99
Amiodarone ATC: C01BD01
Other diseases and medication
Lithium ATC: N05AN01
Corticosteroids ATC: H02AB
doi:10.1371/journal.pone.0129793.t002
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A number of sensitivity analyses were performed to validate the primary findings. First, we
adjusted the main model for ischemic heart disease and socioeconomic status at baseline. Sec-
ond, we did an identical sensitivity analysis using only patients with a Charlson Comorbidity
Index equal zero, corresponding to no known comorbidities. Third, run-in periods of three,
nine and twelve months from the time of the first thyroid function test until the time of the
first prescription of levothyroxine were used. Fourth, time was divided into smaller intervals in
order to ensure a constant rate in time division (bands were split every three- and six months
from 1 January 2000). Finally, we obtained test results for a second thyroid function test, within
3 months from the first, in order to verify the thyroid function status of the patient group ini-
tially classified with subclinical hypothyroidism.
All statistical analyses were performed with the SAS Statistical Software package version 9.2
(SAS Institute Inc., Gary, NC, USA) and Stata Software version 11 (StataCorp, College Station,
TX, USA).
Ethics
The Danish Data protection Agency approved this study (Ref. No. 2007-58-0015/GEH-2014-
018; I-Suite No. 02736) and data were made available for this study in an anonymised format
preventing identification of individuals. Retrospective studies do not require ethical approval
in Denmark.
Results
A total of 628,935 individuals were included at first-time thyroid function test out of which
12,212 (1.9%) were classified with subclinical hypothyroidism. Selection of the study cohort is
illustrated in Fig 1 and the baseline characteristics of the cohort are presented in Table 3.
The study population comprised mainly women (79.8%) and the mean age was 55.2 years
(SD ± 18.8). The treated patient group had slightly less comorbidity and was a few years youn-
ger with the exception of men with Grade I. Otherwise, the two groups had no major distinc-
tions in health.
Within the first six months from the date of thyroid function test, 2,483 (20.3%) patients
claimed prescriptions for levothyroxine. Out of these, 8% were treated for a maximum of 30
days, 6% were treated between 31 and 180 days, 7% were treated between 181 and 365 days,
13% were treated for 1–2 years, 13% were treated for 2–3 years and 54% were treated for more
than 3 years. The average treatment time was 1,355 (IQR: 1,636) days and the average daily
dosage prescribed was 79.7 (SD ± 30.8) micrograms.
The 9,729 patients defined as untreated either initiated levothyroxine treatment later than
six months after their initial thyroid function test (3,799, corresponding to 39.0% of the origi-
nal 9,729), or did not initiate any substitution treatment (5,930 corresponding to 61% of the
original 9,729).
During a median follow-up of 5.0 (IQR: 5.2) years, 358 myocardial infarctions were regis-
tered, and a total of 1.566 (12.8%) patients died. Out of these deaths 766 were
cardiovascular related.
Some 205 patients were lost to follow-up due to emigration and were censored.
All-cause mortality
The unadjusted incidence rates for all-cause mortality in subclinical hypothyroidism were
26.4/1000 py for the untreated group and 22.3/1000 py for the treated group. Considering pa-
tients with Grade I the unadjusted incidence rates were 26.7/1000 py and 21.8/1000 py for the
Levothyroxine Substitution in Patients with Subclinical Hypothyroidism
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untreated and treated groups respectively while the unadjusted incidence rates for Grade II
were 24.9/1000 py and 22.9/1000 py for the untreated and treated groups respectively.
The adjusted Incidence Rate Ratios did not show any influence of treatment for neither the
overall group of patients with subclinical hypothyroidism (IRR 1.03 [95% CI: 0.90 to 1.19]),
nor the patients with Grade I (IRR 1.06 [95% CI: 0.87 to 1.28]), nor Grade II (IRR 1.04 [95%
CI: 0.82 to 1.31]), see Fig 2.
When patients were divided into age groups, the results for overall subclinical hypothyroid-
ism showed that treated patients under the age of 65 years had a significant lower mortality
when compared to untreated patients under the age of 65 years (IRR 0.63 [95% CI: 0.40 to
0.99]). When considering patients under the age of 65 years with Grade I (IRR 0.59 [95% CI:
0.32 to 1.09]) and Grade II (IRR 0.82 [95% CI: 0.38 to 1.76]) isolated, this finding was no longer
significant. The results for patients over the age of 65 years were similar to the main results, see
Fig 2.
Fig 1. Flowchart. Selection of the study population.
doi:10.1371/journal.pone.0129793.g001
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Myocardial infarction
The unadjusted incidence rates for myocardial infarction in subclinical hypothyroidism were
6.1/1000 py for the untreated group and 5.4/1000 py for the treated group. Considering pa-
tients with Grade I the unadjusted incidence rates were 6.0/1000 py and 4.5/1000 py for the un-
treated and treated groups respectively while the unadjusted incidence rates for Grade II were
6.4/1000 py and 6.2/1000 py for the untreated and treated groups respectively.
The adjusted Incidence Rate Ratios did not show any influence of treatment for neither the
overall group of patients with subclinical hypothyroidism (IRR 1.08 [95% CI: 0.81 to 1.44]),
nor the patients with Grade I (IRR 0.94 [95% CI: 0.62 to 1.43]), nor Grade II (IRR 1.18 [95%
CI: 0.75 to 1.86]). Grouping by age yielded no significant differences in the main results, see
Fig 2.
Table 3. Baseline characteristics.
Subclinical Hypothyroidism Subclinical Hypothyroidism Total Population
Grade I Grade II
Treated Un-treated Treated Un-treated
(n = 1,315) (n = 8,310) (n = 1,168) (n = 1,419) (n = 12,212)
Age (±SD), years
Mean age 53.0 (17.3) 55.3 (19.2) 54.4 (17.5) 57.0 (18.2) 55.2 (18.8)
Min.-max. age 18–96 18–102 20–99 18–100 18–102
Mean age, Women 52.4 (17.8) 55.7 (19.3) 54.5 (17.6) 57.1 (18.4) 55.4 (18.9)
Mean age, Men 57.0 (17.4) 54.1 (18.7) 53.6 (17.0) 56.6 (17.8) 54.5 (18.4)
Sex, No. (%)
Women 1141 (86.8) 6457 (77.7) 1004 (86.0) 1141 (80.4) 9,743 (79.8)
Men 174 (13.2) 1853 (22.3) 164 (14.0) 278 (19.6) 2,469 (20.2)
Thyroid Function, median (IQR)
TSH, mIU/L 7.3 6.2 17.0 14.0 6.9
(6.2–8.7) (5.5–7.4) (13.0–25.0) (12.0–18.0) (5.7–9.7)
FT4, pmol/L 12.3 13.5 11.0 11.9 13.0
(11.1–13.6) (12.2–15.0) (10.0–12.2) (10.8–13.2) (11.5–14.5)
Comorbidity, No (%)
Ischemic heart disease 56 (4.3) 551 (6.6) 57 (4.9) 90 (6.3) 750 (6.1)
Heart Failure 25 (1.9) 263 (3.2) 17 (1.5) 39 (2.7) 344 (2.8)
Stroke 23 (1.7) 250 (3.0) 32 (2.7) 45 (3.2) 350 (2.9)
Diabetes 49 (3.7) 324 (3.9) 31 (2.7) 55 (3.9) 459 (3.8)
Myocardial Infarction 24 (1.8) 248 (3.0) 30 (2.1) 42 (3.0) 344 (2.8)
Charlson Comorbidity index No. (%)
0 1,228 (93.4) 7,705 (92.7) 1,093 (93.6) 1,323 (93.2) 11,349 (93)
1 44 (3.4) 295 (3.5) 36 (3.1) 52 (3.7) 427 (3.5)
2 28 (2.1) 212 (2.6) 34 (2.9) 34 (2.4) 308 (2.6)
3+ 15 (1.1) 98 (1.2) 5 (0.4) 10 (0.7) 128 (1.0)
Yearly income on quintiles, No. (%)
0 (lowest) 150 (11.4) 1,145 (13.8) 109 (9.3) 151 (10.6) 1,555 (12.7)
1 263 (20.0) 2,168 (26.1) 259 (22.2) 408 (28.7) 3,098 (25.6)
2 282 (21.5) 1,841 (22.1) 257 (22.0) 332 (23.4) 2,712 (22.1)
3 333 (25.3) 1,602 (19.3) 265 (22.7) 276 (19.5) 2,476 (20.2)
4 (highest) 287 (21.8) 1,554 (18.7) 278 (23.8) 252 (17.8) 2,371 (19.4)
doi:10.1371/journal.pone.0129793.t003
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Fig 2. Incidence Rates (IRs) and Incidence Rate Ratios (IRR). Stratified on treatment, two grades of subclinical hypothyroidism, age and adjusted for
gender, age, Charlson Comorbidity Index and calendar year. CI = Confidence Interval, py = person-years.
doi:10.1371/journal.pone.0129793.g002
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Cardiovascular death
The unadjusted incidence rates for cardiovascular death in subclinical hypothyroidism were
13.0/1000 py for the untreated group and 10.4/1000 py for the treated group. Considering pa-
tients with Grade I the unadjusted incidence rates were 13.2/1000 py and 11.1/1000 py for the
untreated and treated groups respectively while the unadjusted incidence rates for Grade II
were 11.9/1000 py and 9.8/1000 py for the untreated and treated groups respectively.
The adjusted Incidence Rate Ratios did not show any influence of treatment for neither the
overall group of patients with subclinical hypothyroidism (IRR 1.02 [95% CI: 0.83 to 1.25]),
nor the patients with Grade I (IRR 1.15 [95% CI: 0.88 to 1.51]), nor Grade II (IRR 0.94 [95%
CI: 0.66 to 1.34]). Grouping by age yielded no significant differences in the main results, see
Fig 2.
Sensitivity analyses
Adjusting the main model for ischemic heart disease and socioeconomic status at baseline did
not produce any significant impact on the results obtained with the main model nor did in-
cluding only patients with Charlson Comorbidity Index equal zero. The gender-stratified anal-
ysis showed no difference from our main results, with one exception where it appeared that
levothyroxine treated men classified with Grade I had a higher risk of cardiovascular death (17
events among treated and 137 events among untreated) when compared to untreated men in
the same classification (IRR 1.69 [95% CI: 1.02 to 2.80]).
Using different run-in periods between thyroid function test and initiation of levothyroxine
(three, nine and twelve months) did not affect the main results. Also, the main results were not
altered when time was divided into smaller intervals.
Out of 12,212 patients initially classified with subclinical hypothyroidism, 3,443 (28.2%)
had a second thyroid function test within three months from the first test. Out of these, 1.675
(48.6%) patients were confirmed subclinical hypothyroid. Conducting the same analysis for
this group yielded no differences from the main results, see Table 4. Interactions of levothyrox-
ine treatment with age and gender were examined, and no clinical important interactions
were found.
Discussion
In this large cohort study no association between levothyroxine treatment and risk of myocar-
dial infarction (MI) and mortality was found, except in younger patients where it may seem
that levothyroxine has a marginal protective effect on all-cause mortality.
Previous cohort studies on subclinical hypothyroidism and hard endpoints have been con-
flicting with some reporting increased longevity[16, 41] and some finding no association.[42,
43] Interestingly, a recent cohort study by Razvi et al. on 4,735 primary care patients in the UK
found fewer ischemic heart disease events and reduced all-cause mortality in younger (40–70
years) subclinical hypothyroid patients substituted with levothyroxine.[44] The findings in our
study, which show that levothyroxine has a marginal protective effect on all-cause mortality on
patients under the age of 65 years, are partly in keeping with those of Razvi et al.. A similar pro-
tective effect could not be demonstrated when considering MI and cardiovascular death. Nei-
ther was the protective effect on all-cause mortality in younger patients significant when
stratifying on Grade I and Grade II subclinical hypothyroidism. On the other hand, one sensi-
tivity analysis showed that levothyroxine treated men classified with Grade I subclinical hypo-
thyroidism had a higher risk of cardiovascular death. One explanation for this finding may be
that we studied a small group (n = 174) with slightly more cardiovascular comorbidities and
therefore might observe negative side effects of levothyroxine on the cardiovascular system.
Levothyroxine Substitution in Patients with Subclinical Hypothyroidism
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Table 4. Sensitivity analyses.
Subclinical hypothyroidism
All-cause mortality Grade I Grade II Overall
Main results 1.06 (0.87–
1.28)
1.04 (0.82–
1.31)
1.03 (0.90–
1.19)
Adjusted for ischemic heart disease at baseline 1.05 (0.64–
1.72)
0.79 (0.42–
1.47)
0.96 (0.66–
1.39)
Adjusted for socioeconomic status at baseline 1.05 (0.87–
1.27)
1.05 (0.83–
1.33)
1.03 (0.90–
1.19)
Individuals with no known comorbidities 1.08 (0.87–
1.34)
1.19 (0.92–
1.54)
1.13 (0.96–
1.32)
Stratiﬁed by gender
Women 0.97 (0.78–
1.21)
1.02 (0.79–
1.31)
0.99 (0.85–
1.16)
Men 1.42 (0.97–
2.07)
1.17 (0.61–
2.24)
1.24 (0.89–
1.71)
Time to ﬁrst prescription
3 months 0.96 (0.76–
1.20)
0.99 (0.78–
1.26)
0.96 (0.82–
1.13)
9 months 1.01 (0.84–
1.22)
1.08 (0.86–
1.36)
1.02 (0.90-1-
17)
12 months 1.03 (0.87–
1.23)
1.10 (0.88–
1.38)
1.04 (0.91–
1.18)
Stratiﬁed by follow-up time
3 months 1.06 (0.87–
1.28)
1.03 (0.82–
1.31)
1.03 (0.90–
1.19)
6 months 1.06 (0.87–
1.28)
1.03 (0.82–
1.31)
1.03 (0.90-1-
19)
Using only patients with diagnoses conﬁrmed in a second
thyroid function test
- - 0.90 (0.66–
1.22)
MI Grade I Grade II Overall
Main results 1.66 (0.70–
3.95)
1.45 (0.49–
4.31)
1.42 (0.76–
2.68)
Adjusted for ischemic heart disease at baseline 0.86 (0.40–
1.87)
0.81 (0.36–
1.84)
0.89 (0.53–
1.51)
Adjusted for socioeconomic status at baseline 0.94 (0.62–
1.43)
1.21 (0.77–
1.90)
1.08 (0.81–
1.44)
Individuals with no known comorbidities 0.93 (0.57–
1.51)
1.07 (0.66–
1.73)
1.09 (0.79–
1.51)
Stratiﬁed by gender
Women 0.84 (0.50–
1.41)
1.05 (0.63–
1.78)
0.98 (0.70–
1.38)
Men 1.21 (0.58–
2.51)
1.66 (0.70–
3.92)
1.41 (0.83–
2.40)
Time to ﬁrst prescription
3 months 1.70 (0.71–
4.05)
2.40 (0.78–
7.40)
1.68 (0.89–
3.16)
9 months 1.55 (0.69–
3.46)
1.44 (0.49–
4.29)
1.36 (0.74–
2.51)
12 months 1.34 (0.60–
2.99)
1.44 (0.49–
4.29)
1.27 (0.69–
2.34)
Stratiﬁed by follow-up time
3 months 1.65 (0.69–
3.95)
1.45 (0.49–
4.32)
1.42 (0.76–
2.68)
(Continued)
Levothyroxine Substitution in Patients with Subclinical Hypothyroidism
PLOSONE | DOI:10.1371/journal.pone.0129793 June 12, 2015 10 / 17
Another possibility is that this finding might be a chance finding, since it was not possible to
recreate the same association considering MI and all-cause mortality. The above mentioned re-
sults from the study by Razvi et al. is also in keeping with a large meta-analysis of twelve ran-
domized controlled trials, comparing thyroid hormone treatment with placebo in 350
participants with subclinical hypothyroidism made by Villar et al.[45].
Although subclinical hypothyroidism is associated with a number of well-known cardiovas-
cular risk factors, we could not demonstrate an effect on the risk of MI and cardiovascular
death in patients treated with levothyroxine. This was unexpected, as several studies have
shown that levothyroxine decreases total plasma cholesterol in patients with hypercholesterol-
emia and subclinical hypothyroidism,[8, 46] Although we were not able to demonstrate a bene-
ficial effect on all-cause mortality, MI and cardiovascular death in these patients, it is
important to remember that there may be other benefits of treating subclinical hypothyroidism
such as e.g. physical wellbeing and mitigation of general fatigue.[47, 48]
The potential harmful effects of treatment (and overtreatment) with levothyroxine are well-
known and include cardiovascular and skeletal side effects.[49, 50] A clinical case-control
Table 4. (Continued)
Subclinical hypothyroidism
6 months 1.66 (0.69–
3.95)
1.45 (0.49–
4.31)
1.42 (0.76–
2.68)
Using only patients with diagnoses conﬁrmed in a second
thyroid function test
- - 0.72 (0.39–
1.34)
CV Death Grade I Grade II Overall
Main results 1.15 (0.88–
1.51)
0.94 (0.66–
1.34)
1.02 (0.83–
1.25)
Adjusted for ischemic heart disease at baseline 1.09 (0.59–
2.03)
1.05 (0.51–
2.14)
1.15 (0.74–
1.78)
Adjusted for socioeconomic status at baseline 1.14 (0.87–
1.49)
0.93 (0.65–
1.33)
1.01 (0.83–
1.24)
Individuals with no known comorbidities 1.20 (0.88–
1.62)
1.03 (0.70–
1.51)
1.11 (0.88–
1.39)
Stratiﬁed by gender
Women 1.02 (0.74–
1.40)
0.97 (0.67–
1.41)
0.96 (0.77–
1.21)
Men 1.69 (1.02–
2.80)*
0.78 (0.26–
2.27)
1.32 (0.83–
2.08)
Time to ﬁrst prescription
3 months 1.10 (0.80–
1.49)
0.82 (0.56–
1.19)
0.93 (0.74–
1.17)
9 months 1.06 (0.82–
1.38)
1.00 (0.71–
1.40)
0.99 (0.82–
1.21)
12 months 1.08 (0.84–
1.38)
1.08 (0.77–
1.51)
1.03 (0.85–
1.24)
Stratiﬁed by follow-up time
3 months 1.15 (0.88–
1.51)
0.94 (0.66–
1.34)
1.02 (0.83–
1.25)
6 months 1.15 (0.88–
1.51)
0.94 (0.66–
1.34)
1.02 (0.83–
1.25)
Using only patients with diagnoses conﬁrmed in a second
thyroid function test
- - 0.89 (0.58–
1.38)
doi:10.1371/journal.pone.0129793.t004
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study by Biondi et al. involving twenty patients substituted with levothyroxine and twenty nor-
mal controls, demonstrated an increased risk of cardiac side-effects, such as tachycardia and
atrial arrhythmias, in the patients substituted with suppressive doses of levothyroxine.[49] A
Danish meta-analysis of thirteen cross-sectional studies by Faber and Galløe[51] showed re-
duction in bone mass due to reduced serum TSH owing to levothyroxine treatment in post-
menopausal women. Another study by Ross et al. involving 28 premenopausal women
prescribed with levothyroxine found a 9% reduction in bone density compared with normal
premenopausal age-matched controls.[50] These findings might bring concern that levothyr-
oxine treatment, suppressing serum TSH, might promote osteoporosis. Studies have shown
that around 40–48% of substituted hypothyroid patients have abnormal TSH levels. [52, 53]
The Colorado Survey showed that out of 1,525 patients substituted with levothyroxine, 17.6%
had subclinical hypothyroidism and 20.7% had subclinical hyperthyroidism.[52] This finding
is in keeping with an observational study by Parle et al., which found that in 146 patients treat-
ed with levothyroxine, 21% were over-treated.[53] These data suggest that there exists a ten-
dency towards overtreatment with levothyroxine, which may lead to both cardiac- and skeletal
side effects, but also weight loss, which patients may welcome.[54]
International guidelines recommend considering treatment of subclinical hypothyroidism
when TSH> 10 mIU/L (except in elderly patients). For patients with TSH 10 mIU/L the
treatment should be planned on an individual level, mainly based on symptomatology.[20, 21,
55] Looking at the patients with Grade II subclinical hypothyroidism (TSH> 10 mIU/L) in
this present study, less than half of these patients are treated, even though the current guide-
lines recommend treatment. This may reflect the uncertainty and disagreement among doctors
behind the decision to initiation of treatment.
The overall main results in our study partly support the current guidelines, which state that
treatment decisions should be kept on an individual level and always consider the symptomatolo-
gy and comorbidities of the individual patient. Given the fact that this study shows no convincing
overall influence of levothyroxine on the risk of MI, cardiovascular death and all-cause mortality,
the decision to treat a patient should primarily be based on a desire to relieve symptoms.
Strengths and limitations of the study
The large cohort and the availability of complete follow-up data are the main strengths of this
study. Specifically, we had access to thyroid function tests from approximately half of the indi-
viduals in the capital region of Denmark and the use of levothyroxine and outcomes represent
real-world data from primary care.
It is essential to notice that we did not have any knowledge of the reasons for thyroid func-
tion testing, how the patients were monitored while undergoing treatment or how the patients’
hormonal levels responded to treatment i.e. whether treated patients became euthyroid or re-
mained subclinical hypothyroid. Therefore, the possibility that the results were influenced by
selection bias cannot be excluded. Furthermore, the selection of subjects for thyroid function
testing by physicians could in itself be associated with the studied outcomes of interest. Addi-
tionally, we did not have access to a number of relevant clinical information such as blood pres-
sure, BMI, serum lipid, smoking status, electrocardiography, or the specific cause of thyroid
dysfunction, as we do not hold information regarding radioiodine treatment or thyroid autoan-
tibody levels. However, a previous similar study did not found that BMI, smoking status, total
cholesterol or blood pressure, were important confounders.[44]
This study has a relatively short mean follow-up period of 5.0 years and it should be ac-
knowledged that the outcomes studied might occur after longer periods of thyroid disease and
levothyroxine treatment.
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The results of this study could be explained by the fact that patients with subclinical hypo-
thyroidism may experience spontaneous normalization of TSH values and regress to euthyr-
oidism without treatment, which could underestimate the examined endpoints. On the other
hand, some patients with subclinical hypothyroidism might progress to overt hypothyroidism,
which could overestimate the risk in this study.[56] Another limitation is the definition of the
treated patient group. The six-month run-in period from the first thyroid function test in
which the patients could initiate treatment with levothyroxine was chosen to make certain that
the subsequent treatment was associated with the specific thyroid function test and not initiat-
ed due to e.g. overt hypothyroidism developed during the follow-up period. This means that
patients who initiated treatment after six months were not considered in the treated group.
However, sensitivity analyses using three, nine and twelve month run-in periods did not
change the main results. In individuals with subclinical hypothyroidism who initiated substitu-
tion treatment within the first 6 months the average dose of levothyroxine was estimated to 80
micrograms/day, which seems reasonable, considering that 100–150 micrograms pr. day are
often needed in overt hypothyroidism.[57]
It was not possible to verify the thyroid function status of all patients due to incomplete
data, but an analysis using only patients with confirmed subclinical hypothyroidism by control
blood tests showed no significantly changes in the main results.
A confounder which could affect the results might be the fact that doctors could be more
likely to prescribe treatment to patients with inability to follow a healthy lifestyle such as those
with overweight, smoking and physical inactivity. If that is indeed the case, the risks associated
with the patients’ basic lifestyle might suppress the hypothesized beneficial effect of treatment.
The study included only individuals in primary care setting, and therefore extrapolation of
these results to patients from in- or outpatient clinics should be performed with caution. Like-
wise, extrapolation of these results to other ethnic groups than Caucasians should be done with
care since the Danish population comprises mainly this group.
There may be other health benefits of treating subclinical hypothyroidism, such as changes
in cholesterol levels, symptom relief, weight loss, or quality of life in general, which this study
does not consider. Treatment may well have a positive effect on the above parameters, which in
itself can have a significant impact on the patient. Patient-based decisions with consideration
of the individual history should be made when starting treatment with levothyroxine, as the
goals of treatment are not necessarily the outcomes examined in this study.
Conclusion
In conclusion, substitution treatment with levothyroxine in patients with subclinical hypothy-
roidism, is not associated with lower mortality or decreased risk of myocardial infarction. Clin-
ical randomized controlled trials are needed to confirm the findings of this study.
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